TY - JOUR
T1 - Global survival trends for brain tumors, by histology
T2 - analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3)
AU - Girardi, Fabio
AU - Matz, Melissa
AU - Stiller, Charles
AU - You, Hui
AU - Marcos Gragera, Rafael
AU - Valkov, Mikhail Y
AU - Bulliard, Jean-Luc
AU - De, Prithwish
AU - Morrison, David
AU - Wanner, Miriam
AU - O'Brian, David K
AU - Saint-Jacques, Nathalie
AU - Coleman, Michel P
AU - Allemani, Claudia
AU - CONCORD Working Group
AU - Da Costa, Allini Mafra
N1 - © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology.
PY - 2023/3/14
Y1 - 2023/3/14
N2 - BACKGROUND: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology.METHODS: We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator.RESULTS: The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults.CONCLUSIONS: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
AB - BACKGROUND: Survival is a key metric of the effectiveness of a health system in managing cancer. We set out to provide a comprehensive examination of worldwide variation and trends in survival from brain tumors in adults, by histology.METHODS: We analyzed individual data for adults (15-99 years) diagnosed with a brain tumor (ICD-O-3 topography code C71) during 2000-2014, regardless of tumor behavior. Data underwent a 3-phase quality control as part of CONCORD-3. We estimated net survival for 11 histology groups, using the unbiased nonparametric Pohar Perme estimator.RESULTS: The study included 556,237 adults. In 2010-2014, the global range in age-standardized 5-year net survival for the most common sub-types was broad: in the range 20%-38% for diffuse and anaplastic astrocytoma, from 4% to 17% for glioblastoma, and between 32% and 69% for oligodendroglioma. For patients with glioblastoma, the largest gains in survival occurred between 2000-2004 and 2005-2009. These improvements were more noticeable among adults diagnosed aged 40-70 years than among younger adults.CONCLUSIONS: To the best of our knowledge, this study provides the largest account to date of global trends in population-based survival for brain tumors by histology in adults. We have highlighted remarkable gains in 5-year survival from glioblastoma since 2005, providing large-scale empirical evidence on the uptake of chemoradiation at population level. Worldwide, survival improvements have been extensive, but some countries still lag behind. Our findings may help clinicians involved in national and international tumor pathway boards to promote initiatives aimed at more extensive implementation of clinical guidelines.
KW - Humans
KW - Adult
KW - Glioblastoma
KW - Brain Neoplasms/therapy
KW - Astrocytoma/therapy
KW - Global Health
KW - Registries
UR - https://pubmed.ncbi.nlm.nih.gov/3635536
U2 - 10.1093/neuonc/noac217
DO - 10.1093/neuonc/noac217
M3 - Article
C2 - 36355361
SN - 1522-8517
VL - 25
SP - 580
EP - 592
JO - Neuro-Oncology
JF - Neuro-Oncology
IS - 3
ER -